Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc.
Your view on VRCA
Overview
What the company does, where it operates, and who runs it.
About Verrica Pharmaceuticals Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jayson M. Rieger
- Headquarters
- 44 West Gay Street, West Chester, PA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jayson M. Rieger
- Headquarters
- 44 West Gay Street, West Chester, PA, US
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States.
The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts.
The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications.
Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Verrica Pharmaceuticals Inc., and the rating behind it. VRCA last traded at $4.91; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Verrica Pharmaceuticals Inc.. Starting points for Verrica Pharmaceuticals Inc.: EPS -$1.46, beta 1.50 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Verrica Pharmaceuticals Inc.. Verrica Pharmaceuticals Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Verrica Pharmaceuticals Inc.. Trailing twelve-month EPS for Verrica Pharmaceuticals Inc. stands at -$1.46. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Verrica Pharmaceuticals Inc.. Verrica Pharmaceuticals Inc. has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Verrica Pharmaceuticals Inc. valued side by side against its closest peers. Verrica Pharmaceuticals Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Verrica Pharmaceuticals Inc., and how their positions are changing. At a $84.3M market value, institutional positions materially move Verrica Pharmaceuticals Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Verrica Pharmaceuticals Inc. executives and directors. Shares of Verrica Pharmaceuticals Inc. have traded between $3.28 and $13.60 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Verrica Pharmaceuticals Inc.. Verrica Pharmaceuticals Inc. is a $84.3M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Verrica Pharmaceuticals Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Verrica Pharmaceuticals Inc.. Coverage tracks Verrica Pharmaceuticals Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.